Micron Technologies

Micron Technologies (“Micron”) focuses on solving the pharmaceutical industry’s most difficult bio-availability and drug delivery challenges through multiple particle size reduction technologies.

Micron is a leading independent provider of micronization services for solubility enhancement of active pharmaceutical ingredients (“APIs”). Micron maintains state of the art facilities, in the US and UK, offering industry leading capabilities including distinctive containment technology for processing highly potent compounds.

In 2014, Micron was sold to Catalent  (NYSE:CTLT), a provider of advanced delivery technologies and development solutions for drugs and consumer health products.